The Jiangnan Beauty Bay, a beauty and healthcare industrial park, officially opened in Xinwu district, Wuxi, Jiangsu province ...

WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the ...

WuXi AppTec (Shanghai, China) has sold off two US/UK businesses in February and March, it revealed in its annual results on ...

The successful launch of the 2025 Wuxi "International Month" and International Cherry Blossom Viewing Week marks a ...

Shortly after WuXi AppTec provided an upbeat outlook for 2025, several other WuXi sibling companies are coming forward with ...

Jefferies analyst Cui Cui maintained a Buy rating on Wuxi Biologics (Cayman) (WXIBF – Research Report) today and set a price target of ...

The event, which originated in the 1980s from citizen-level exchanges between China and Japan, centers on the planting of ...

An affectionate moment between a middle-aged male runner and a young female companion at the 2025 Wuxi Marathon sparked ...

WuXi Biologics reports 32.5% North American revenue growth in 2024, driven by deals with BioNTech and Candid Therapeutics, ...

We have raised our fair value estimate for narrow-moat-rated WuXi Biologics to HKD 26.60 per share from HKD 24.60 following better-than-expected 2024 results and strong guidance for 2025.

WuXi Biologics differentiates itself from other well-established global contract development and manufacturing organizations, with its "follow-and-win the molecule" and "global dual-sourcing ...